SG Americas Securities LLC Acquires 152,170 Shares of Novo Nordisk A/S $NVO

SG Americas Securities LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 6.4% during the 4th quarter, HoldingsChannel reports. The fund owned 2,535,346 shares of the company’s stock after purchasing an additional 152,170 shares during the period. SG Americas Securities LLC’s holdings in Novo Nordisk A/S were worth $128,998,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. True Wealth Design LLC lifted its stake in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the last quarter. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $25,000. Strengthening Families & Communities LLC bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $30,000. Allianz SE raised its holdings in Novo Nordisk A/S by 70.0% during the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after buying an additional 238 shares during the period. Finally, Financial Life Planners bought a new stake in Novo Nordisk A/S in the third quarter worth $33,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA clears a higher-dose formulation of Wegovy, which can deepen Novo Nordisk’s obesity franchise and support sales/price power for its semaglutide lineup. FDA Clears NVO’s Higher Dose of Wegovy
• Positive Sentiment: Novo Nordisk launched a Phase 1 study of LX9851, an oral non‑incretin obesity candidate licensed from Lexicon, expanding the pipeline beyond injectable semaglutides and offering long‑term upside if oral assets succeed. Lexicon and Novo Nordisk Announce Phase 1
• Positive Sentiment: Ongoing share repurchase programme (part of up to DKK 15bn plan) supports EPS and signals management confidence, which can be a near‑term technical tailwind. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Analyst and valuation pieces are mixed: some highlight Novo’s entrenched market position and recent approvals, while others warn of slowing growth and competition—contributing to divergent investor views on valuation. Novo Nordisk Valuation Check As LX9851 Expands
• Negative Sentiment: Indian patent expiry has opened the floodgates: multiple Indian manufacturers launched low‑cost generics of Ozempic/Wegovy (semaglutide), cutting prices by ~70% locally and setting a precedent for aggressive generic competition in price‑sensitive markets. This raises long‑term pricing and volume risk outside core markets. Indian drugmakers flood market with cheaper versions
• Negative Sentiment: Multiple reports emphasize cheap generic launches in India and other local markets (coverage by CNBC, DrugStoreNews, Moby), underscoring immediate revenue pressure where patent protection has lapsed and the risk of parallel imports or international pricing pressure over time. India launching cheap weight-loss drugs

Novo Nordisk A/S Stock Performance

NVO stock opened at $36.81 on Tuesday. Novo Nordisk A/S has a twelve month low of $35.85 and a twelve month high of $81.44. The firm has a market cap of $164.36 billion, a price-to-earnings ratio of 10.61 and a beta of 0.73. The business’s fifty day simple moving average is $47.76 and its two-hundred day simple moving average is $50.93. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is 52.74%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on NVO shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. HSBC restated a “hold” rating and issued a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. CICC Research assumed coverage on shares of Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 price target for the company. Sanford C. Bernstein assumed coverage on shares of Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. Finally, Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Four analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.